Drives intestinal inflammation and predicts response to tumour necrosis factor-neutralising therapy; Mediates STAT3-dependent intestinal epithelial restitution; Predicts Crohn’s disease response to Infliximab; Biomarker of poor biochemical response to Infliximab. The gene discussed is STAT3; the disease is Crohn disease.